Parkinson's disease

News

AC Immune's chief executive Dr Andrea Pfeifer

AC Immune says Parkinson's drug slows progression

AC Immune's active immunotherapy study backs up the alpha-synuclein hypothesis in Parkinson's disease, after disappointments in earlier trials.

News

Merck partners Valo on $3bn, AI-based Parkinson's project

Merck has teamed up with Valo Health on a project to apply AI to the discovery of novel drug targets and drugs for Parkinson's.

News

UK starts 'largest-ever' trial of possible Parkinson's drugs

UK researchers have started a large-scale trial to test a battery of potential Parkinson's drugs to see if they can slow down disease progression.

R&D

pharmaphorum podcast Episode 209a, Gene Mack

Allosteric small molecule therapies in PD, with Gene Mack

pharmaphorum looks back to a conversation with Gain Therapeutics' CEO Gene Mack earlier in the year, on research in the Parkinson's disease space.

News

Bayer starts pivotal Parkinson's cell therapy trial

Bayer's much-anticipated stem cell therapy for Parkinson's disease is gathering momentum, with dosing in phase 3 trials now underway.

News

NRG raises £50m to start trials of Parkinson's, ALS drug

NRG Therapeutics' oversubscribed Series B will fund first-in-human trials of a drug targeting mitochondrial dysfunction in neurodegenerative diseases.

AC Immune says Parkinson's drug slows progression

Merck partners Valo on $3bn, AI-based Parkinson's project

UK starts 'largest-ever' trial of possible Parkinson's drugs

Allosteric small molecule therapies in PD, with Gene Mack

Bayer starts pivotal Parkinson's cell therapy trial

NRG raises £50m to start trials of Parkinson's, ALS drug

CHMP decision levels the playing field for GSK's RSV jab

How to meet your physicians where they are online

Parkinson's disease

Editor's Picks